IQ-AI Limited - StoneChecker USA Market Introduction
("IQ-AI" or the "Company")
Every year in the
The equipment used for this procedure costs in excess of
StoneChecker was developed to examine the computed tomography (CT) images used to diagnose the presence of the kidney stone and evaluate the likelihood they would break up during a lithotripsy procedure. Cost efficiencies can be realized by using advanced imaging to non-invasively screen patients who are unlikely to have a successful lithotripsy procedure, or by avoiding the much more expensive and invasive surgical procedure by accurately screening those patients who would be successful with lithotripsy.
Relationships with key strategic partners for StoneChecker have been cultivated for some time, including discussions with companies that are CT technology providers, suppliers of lithotripsy equipment and companies specializing in the kidney sector which sell directly to kidney specialists. These discussions are continuing, as we evaluate how best to optimize the commercial opportunities provided by last week's FDA clearance.
The IQ-AI product development program is where projects are born and developed that we hope will yield revenues into the future. This approach has recently produced the Auto-Segmentation, Gadolinium-Free, and AI Programs.
The Board believes that a portfolio approach balances risks and opportunities over several different organ systems, and that the current AI development pipeline could yield further market leading products over the coming months and years.
The creation of a system for new product development is the core strategy for the future growth and expansion plans of IQ-AI, and we look forward to making further announcements as events unfold
¹Extracorporeal shock wave lithotripsy versus flexible ureterorenoscopy in the treatment of untreated renal calculi, Fankhauser et al;
The Directors of the Company accept responsibility for the contents of this announcement.
- ENDS -
For further information, please contact:
Tel: 020 7469 0930
Tel: 020 7220 9797
About IQ-AI Ltd
Please visit www.imagingbiometrics.com for further information.
This information is provided by RNS, the news service of the
Quick facts: IQ-AI Limited
Market Cap: £7.37 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE